Progression of lesion size in untreated eyes with exudative age-related macular degeneration: A meta-analysis using lineweaver-burk plots

JAMA Ophthalmology

Volumn 131, Issue 3, 2013, Pages 335-340

  Liu, Tin Yan A ^a   Shah, Ankoor R ^b   Del Priore, Lucian V ^c  

^a New York Presbyterian Hospital   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ARTICLE; DISEASE COURSE; DRUG SAFETY; EXUDATIVE MACULAR DEGENERATION; HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHAM PROCEDURE; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MODELS, STATISTICAL; RETROSPECTIVE STUDIES; TIME FACTORS; WET MACULAR DEGENERATION;

EID: 84875136942     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.818     Document Type: Article

References (34)

1. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11(2):67-115.
2. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in agerelated macular degeneration. Retina. 2001;21(5):416-434.
3. Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology. 1996;103(12):2042-2053.
4. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640- 1642.
5. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372.e365.
6. Rosenfeld PJ, Brown DM, Heier JS, et al MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355 (14):1419-1431.
7. Brown DM, Heier JS, Ciulla T, et al; CLEAR-IT 2 Investigators. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011;118(6):1089-1097.
8. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109(9):1220-1231.
9. Adelberg DA, Del Priore LV, Kaplan HJ. Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders. Retina. 1995;15(3):198-205.
10. Hsu JK, Thomas MA, Ibanez H, Green WR. Clinicopathologic studies of an eye after submacular membranectomy for choroidal neovascularization. Retina. 1995; 15(1):43-52.
11. Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology. 1994;101(8):1384-1396.
12. Thomas MA, Grand MG, Williams DF, Lee CM, Pesin SR, Lowe MA. Surgical management of subfoveal choroidal neovascularization. Ophthalmology. 1992; 99(6):952-968; discussion 975-956.
13. Treatment of Age-related Macular Degenerationwith Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials: TAP report. Arch Ophthalmol. 1999;117(10):1329-1345.
14. D'Amico DJ, Goldberg MF, Hudson H, et al Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina. 2003;23(1): 14-23.
15. Schmidt-Erfurth U, Michels S, Michels R, Aue A. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol. 2005;15(4):482-485.
16. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27): 2805-2816.
17. Shah AR, Del Priore LV. Progressive visual loss in subfoveal exudation in agerelated macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol. 2007;143(1):83-89.
18. Doris N, Hart PM, Chakravarthy U, et al. Relation between macular morphology and visual function in patients with choroidal neovascularisation of age related macular degeneration. Br J Ophthalmol. 2001;85(2):184-188.
19. Hogg R, Curry E, Muldrew A, et al. Identification of lesion components that influence visual function in age related macular degeneration. Br J Ophthalmol. 2003;87(5):609-614.
20. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol. 2008;92(3):361-364.
21. Bressler NM, Arnold J, Benchaboune M, et al Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patientswith age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes: TAP report no 3. Arch Ophthalmol. 2002; 120(11):1443-1454.
22. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularizationverteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2002;133 (1):168-169.
23. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular agerelated macular degeneration. Ophthalmology. 2006;113(9):1508.e1-25.
24. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
25. Blinder KJ, Bradley S, Bressler NM, et al Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no 1. Am J Ophthalmol. 2003;136(3):407-418.
26. Hawkins BS, Bressler NM, Miskala PH, et al Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in agerelated macular degeneration: ophthalmic findings: SST report no 11. Ophthalmology. 2004;111(11):1967-1980.
27. Klein ML, Jorizzo PA, Watzke RC. Growth features of choroidal neovascular membranes in age-related macular degeneration. Ophthalmology. 1989;96(9):1416-1419; discussion 1420-1411.
28. Vander JF, Morgan CM, Schatz H. Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology. 1989;96(9):1422-1426, discussion 1426-1429.
29. Shah AR, Del Priore LV. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Ophthalmology. 2009;116(10):1901-1907.
30. Sarks SH. New vessel formation beneath the retinal pigment epithelium in senile eyes. Br J Ophthalmol. 1973;57(12):951-965.
31. Brown GC, Brown MM, Sharma S, et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc. 2005; 103:173-184; discussion 184-186.
32. Green WR, Enger C. Age-related macular degeneration histopathologic studies: the 1992 Lorenz E. Zimmerman lecture. Ophthalmology. 1993;100(10):1519-1535.
33. Bynoe LA, Chang TS, Funata M, Del Priore LV, Kaplan HJ, Green WR. Histopathologic examination of vascular patterns in subfoveal neovascular membranes. Ophthalmology. 1994;101(6):1112-1117.
34. Grossniklaus HE, Hutchinson AK, Capone A Jr, Woolfson J, Lambert HM. Clinicopathologic features of surgically excised choroidal neovascular membranes. Ophthalmology. 1994;101(6):1099-1111.